Tagged with oncology,

France Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation. In this conversation, Dominique Bery explains how France is shaping Ipsen’s next phase of growth, from oncology leadership to deeper…

France Jazz Pharmaceuticals’ footprint in France has accelerated over recent years, driven by a sharper focus on rare and complex diseases, a sequence of strategic acquisitions and a growing role in late-stage clinical development across neuroscience and oncology. In this conversation, Franck Cousserans, General Manager France and Benelux, reflects on how…

Hong Kong CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and a growing network of regional partnerships. Stable commercial revenues give the organisation unusual freedom to pursue high conviction science, while…

Europe Cancer is one of Europe’s most urgent health challenges. Responsible for 23 percent of all mortality on the continent, the burden is particularly acute outside the EU5, where access timelines vary dramatically. Countries in Central and Eastern Europe, for example, face some of Europe’s highest cancer mortality rates, largely due…

France With over two decades of international experience in the pharmaceutical industry, Olivier Zambelli brings both strategic vision and a deeply human approach to his role as President and General Manager of Astellas France. Joining at a time of profound transformation for the organisation, he is leading the affiliate through a…

Taiwan Professor Pan Chyr Yang is a clinician-scientist with an MD and PhD in pulmonary medicine, holding joint appointments at Academia Sinica and former university leadership roles in National Taiwan University. Recognised for pioneering non-smoker lung cancer screening methodologies in Asia, he has established national surveillance programmes now adopted across the region.…

France Launched in 2022 under the France 2030 biocluster programme, the Paris-Saclay Cancer Cluster (PSCC) is rapidly positioning itself as a new epicentre for oncology innovation in Europe. Under the leadership of CEO Benjamin Garel, it brings together world-class hospitals, leading universities, and major pharmaceutical partners with the mission of transforming…

USA Michael Petroutsas, President and Head of Astellas Pharma US, reflects on the company’s ongoing transformation and the market’s growing strategic importance within Astellas’ global organisation. He goes on to highlight Astellas’ focused therapeutic portfolio in oncology and specialty medicine, investments in advanced modalities like gene and cell therapy, and commitment…

Switzerland Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation.   For instance, in Bellinzona, the capital of the Italian-speaking Ticino canton, the Institute of Oncology Research (IOR) is working with…

France With France now a cornerstone of its global strategy, Regeneron is accelerating its European expansion under the leadership of Antoine Catton. In less than two years, the affiliate has built full operational capabilities, secured major access milestones, and forged partnerships with leading research institutions, cementing its role within France’s thriving…

USA With a refreshed Ambition and Enterprise Model, Ferring Pharmaceuticals US is entering a new chapter defined by agility, innovation, and a sharper focus on patient needs. President Brent Ragans explains how this vision is setting a course for continued growth in reproductive medicine and uro-oncology.   Ferring has always been…

Taiwan Dr Chiu-Heng Chen (John), CEO of LaunXP, brings a unique perspective to oncology drug development shaped by his personal experience with cancer during his PhD in the UK. Holding advanced degrees from British and Taiwanese institutions in tumour oncology, he founded LaunXP in 2015 to bridge academia and clinical practice,…